Table 2.

Stratification analysis for the association between NEFL gene polymorphisms and neuroblastoma susceptibility for combined subjects

Variables	rs11994014 G>A				rs2979704 T>C				rs1059111 A>T
	GG	AG/AA	Adjusted OR a	P a	TT	CT/CC	Adjusted OR a	P a	AA	AT/TT	Adjusted OR a	P a
	(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)
Age, month
≤18	48/120	76/185	1.03 (0.67-1.58)	0.903	48/117	76/188	0.99 (0.64-1.51)	0.947	48/118	76/187	1.00 (0.65-1.53)	0.997
>18	82/181	167/326	1.13 (0.82-1.56)	0.451	83/182	166/325	1.12 (0.81-1.54)	0.487	84/182	165/325	1.10 (0.80-1.51)	0.559
Gender
Females	50/135	107/207	1.40 (0.94-2.09)	0.099	50/131	107/211	1.33 (0.89-1.99)	0.161	50/132	107/210	1.35 (0.90-2.01)	0.143
Males	80/166	136/304	0.93 (0.66-1.30)	0.662	81/168	135/302	0.93 (0.66-1.30)	0.657	82/168	134/302	0.91 (0.65-1.27)	0.574
Sites of origin
Adrenal gland	49/301	85/511	1.02 (0.70-1.49)	0.918	50/299	84/513	0.98 (0.67-1.43)	0.918	50/300	84/512	0.98 (0.67-1.44)	0.933
Retroperitoneal	24/301	63/511	1.53 (0.93-2.50)	0.092	24/299	63/513	1.52 (0.93-2.48)	0.098	25/300	62/512	1.44 (0.89-2.34)	0.142
Mediastinum	39/301	70/511	1.07 (0.70-1.62)	0.764	39/299	70/513	1.05 (0.69-1.59)	0.822	39/300	70/512	1.06 (0.70-1.60)	0.797
Others	14/301	21/511	0.88 (0.44-1.76)	0.719	14/299	21/513	0.87 (0.44-1.74)	0.696	14/300	21/512	0.88 (0.44-1.75)	0.709
Clinical stages
I+II+4s	53/301	111/511	1.25 (0.87-1.78)	0.230	55/299	109/513	1.16 (0.81-1.65)	0.412	55/300	109/512	1.17 (0.82-1.66)	0.392
III+IV	70/301	119/511	1.01 (0.72-1.40)	0.978	70/299	119/513	1.00 (0.72-1.39)	0.985	70/300	119/512	1.00 (0.72-1.39)	0.998

OR, odds ratio; CI, confidence interval. ^a Adjusted for age and gender, omitting the corresponding stratification factor.